Skip to main content

Mintz Advises BeiGene on Global Strategic Oncology Collaboration with Amgen, Which Includes $2.7 Billion Equity Investment

On October 31, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) and Amgen (NASDAQ: AMGN) announced a global strategic oncology collaboration for the commercialization and development in China of Amgen’s XGEVA® (denosumab), KYPROLIS® (carfilzomib), and BLINCYTO® (blinatumomab), and the joint global development of 20 oncology assets in Amgen’s pipeline, with BeiGene responsible for development and commercialization in China. In connection with the collaboration, Amgen will purchase a 20.5% stake in BeiGene for approximately $2.7 billion in cash at $174.85 per American Depositary Share. The transactions are expected to close in the first quarter of 2020.

Headquartered in Beijing, China, BeiGene is a global biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics.

Mintz served as legal advisor to BeiGene for the collaboration agreement. The Mintz team representing BeiGene was led by Mintz Licensing and Collaborations Practice Member John J. Cheney.

Mintz is one of the leading law firms to the life sciences industry, and as such, the firm’s corporate and licensing attorneys have handled more than $20 billion of transactions in the past few years for life sciences clients, including public offerings, joint ventures, licensing and strategic collaborations, mergers and acquisitions, divestitures, distribution deals, and private financings. 

For more information about Mintz, please visit